Our Innovative Medicines business is made up of two separate commercial organizations, Innovative Medicines International and Innovative Medicines US.

Core therapeutic areas

  • Cardiovascular

    Cardiovascular disease is a global health crisis. Billions of people are affected physically, emotionally and financially. Thanks to a combination of our legacy, global footprint and leading science, Novartis is uniquely positioned to help change this landscape. Our efforts include use of early interventions and development of pioneering treatments, from prevention to management, as well as the creation of innovative access models. Our goal is to reduce and ultimately stop premature death and disability from cardiovascular disease.
  • Hematology

    Novartis is deeply committed to transforming the lives of people living with blood cancers and life-threatening blood disorders. Together with its research partners – Novartis led the era of targeted therapies in cancer and, in investigating how these medicines could transform patient outcomes.
  • Solid tumors

  • Immunology

    Novartis aims to improve outcomes and enhance the lives of those affected by painful and debilitating immunological conditions. As a result, we have already helped transform the standard of care for children and adults suffering from conditions such as psoriatic disease and axial spondyloarthritis, chronic urticaria, and a number of rare autoinflammatory diseases. We continue to focus on discovering and delivering innovative medicines for complex, less-explored immunological diseases where there is significant unmet need, such as hidradenitis suppurativa and Sjögren’s syndrome, lupus and osteoarthritis.
  • Neuroscience

    Novartis has been tackling neurological conditions for more than 80 years. Above all, partnering with patients, healthcare professionals and healthcare systems to deliver life-changing solutions and treatments is at the core of what we do. Together, we can innovate to reimagine neuroscience and improve people’s lives.

Ophthalmology

Novartis is reimagining the treatment and prevention of visual impairment and blindness. We aim to develop life-changing pharmaceuticals and transformative technologies for diseases and conditions from front to back of the eye.

Respiratory

At Novartis, our focus is on improving the lives of the hundreds of millions of people living with respiratory diseases, including chronic obstructive pulmonary disease (COPD) and severe allergic asthma.


 

Novartis Global Product Portfolio and Clinical Pipeline

155

Countries in which products are available

30

New molecular entities in our global clinical pipeline


Understanding hidradenitis suppurativa through Jasmine’s eyes

Jasmine, an HS advocate, journalist and filmmaker, is one of the estimated 1 in 100 of the global population who lives with this debilitating skin disease. HS has affected every aspect of her life since she was a child.

Solving the puzzle of immunotherapy

The question of how to unlock the potential of the body’s own immune system to kill cancer cells is more than a century old. At Novartis, we are building on insight to unlock the potential of immunotherapies for more patients around the world.

A Cell Processing Specialist at work in Novartis’ new cell and gene production facility in Stein, Switzerland.

Novartis Gene Therapies

Novartis Gene Therapies is dedicated to developing and commercializing gene therapies for patients and families devastated by rare and life-threatening neurological genetic diseases.


Innovative Medicines leadership

Marie-France Tschudin
President, Innovative Medicines International and Chief Commercial Officer
Marie-France Tschudin
Victor Bulto
President, Innovative Medicines US
Victor Bulto

 


 

Jobs in Innovative Medicines

Sales, Saudi Arabia, PHARMA
Commercial & General Management, Turkey, PHARMA